A new valve.

An earlier decision.

PROGRESS reopens the timing question for selected patients with moderate aortic stenosis.

THE STORY IN FOCUS

16.7%

23.9%

TAVR / surveillance for death or a

heart-failure event at two years. [1]

Linda Bartlett / NCI via Unsplash. Surgical biopsy context photograph; not TAVR or a PROGRESS participant.

When waiting becomes a clinical question

For someone living with a narrowed aortic valve, the

decision is rarely as simple as choosing a date for a

procedure. It concerns what the heart can tolerate, how

symptoms affect ordinary life and whether an

intervention now offers enough benefit to justify its

burdens. This week's PROGRESS findings make that

timing question more immediate for a defined group of

patients.

What changed on 2 November

The international, open-label randomized trial enrolled

744 people with moderate aortic stenosis and at least

one at-risk feature. Participants received transfemoral

transcatheter aortic-valve replacement, or TAVR, with a

balloon-expandable valve, or clinical surveillance. Their

mean age was 78; 39.1% were women. Edwards

Lifesciences funded the study. [1]

At two years, the estimated rate of death or a

heart-failure event was 16.7% with TAVR and 23.9%

with surveillance, an absolute difference of 7.2

percentage points. Heart-failure events were 10.8%

versus 19.0%; death alone was 8.4% versus 7.3%. The

combined outcome improved, driven by fewer

heart-failure events. The findings do not establish a

mortality benefit. [1]

The condition behind the numbers

NHLBI explains that valve disease can remain stable or

worsen over time, sometimes without initial symptoms.

Medicines may address symptoms and associated heart

conditions; repair or replacement may eventually be

needed. Follow-up continues after a procedure. That

places a new trial within an existing care pathway rather

than replacing the pathway with a headline. [2]

What the result means for the reader

A composite endpoint combines different events into

one measure. Here, a lower combined rate cannot be

translated into a claim that more people survived. The

components need to stay visible. Equally, fewer

heart-failure events can matter in their own right: the

value of an outcome should be described accurately

rather than inflated into a different one. Graymedy's

reading is that this is an important result about treatment

timing in selected patients, with decisions still requiring

individual assessment.